New York, N.Y. – July 10, 2019–Prognos, the leader in AI-powered analytics for early tracking and prediction of disease today announced the presentation of its use of the AWS technology stack to predict patient risk at the Amazon Web Services (AWS) Summit New York on July 11 held at the Jacob Javits Center. The annual summit attracts technologists from diverse cloud computing industries who want to use AWS to further their level of innovation.
Adam Petranovich, chief data scientist at Prognos, will showcase Prognos’ AWS architecture that enables the company to deliver real-time patient predictions. His presentation will highlight Prognos’ use of several core technologies, including Amazon Sagemaker, AWS Lambda and S3 Select, to deliver clinical predictions at scale.
“At Prognos, our goal is to leverage the power of A.I. to determine patients’ risk for certain diseases,” says Petranovich. “Complex predictive models combined with our sizeable dataset allows us to encode and discover relationships often overlooked. However, the machines haven’t won just yet. We combine our proprietary deterministic clinical algorithms with our predictive models to determine or predict risk across billions of other data points from hundreds of millions of patients. We have been able to use several AWS technologies with great success, and we are excited to share our findings with a wide audience of innovators.” The summit is free and intended both for those who are new to the cloud and for veterans. Prognos will join leaders from dozens of other fields as they draw attention to their unique uses of AWS platforms.
Prognos is a healthcare AI company focused on predicting disease to drive decisions earlier in healthcare in collaboration with payers, life sciences and diagnostics companies. The Prognos Registry is the largest source of clinical diagnostics information in 50 disease areas, with nearly 24 billion medical records for 200 million patients. Prognos has 1,000 extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. The company is supported by a $42M investment from Safeguard Scientifics, Inc., Merck Global Health Innovation Fund, Cigna, GIS Strategic Ventures, Hikma Ventures, Hermed Capital, and Maywic Select Investments. Learn more about Prognos at www.prognoshealth.com
Prognos Contact
Stacey Levas,
VP, Marketing
slevas@prognoshealth.com